Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves Outcomes in Pretreated Patients with Metastatic Cancer By Ogkologos - October 14, 2025 205 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROME study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with... July 25, 2024 Efficacy and Safety of FOLFIRI With Durvalumab With or Without Tremelimumab... April 22, 2024 FDA Approves Cemiplimab-rwlc for Advanced Non-Small Cell Lung Cancer With High... February 23, 2021 Joining the dots: How our new research data strategy will unlock... July 7, 2022 Load more HOT NEWS Multiple Myeloma Awareness Month: Inequity and Disparities in Multiple Myeloma Diagnosis,... A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and... Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs Grief Anniversaries
